Memphasys Accelerates Felix™ System Launch with Key Regulatory Submissions

Regulatory Milestones Signal Commercial Momentum

Memphasys Limited has taken significant strides toward commercialising its Felix™ System, a patented sperm selection technology designed to improve assisted reproductive treatments. The company has formally lodged regulatory submissions with the Australian Therapeutic Goods Administration (TGA) and India’s Central Drugs Standard Control Organisation (CDSCO), following its recent CE Mark approval in Europe. These submissions mark critical steps toward unlocking sales in two of the world’s most promising IVF markets.

In Australia, Memphasys expects TGA approval by April 2026, which would enable the company to activate pending contracts and expand its footprint in a market characterised by advanced clinical standards and strong reimbursement frameworks. Meanwhile, the Indian submission targets a regulatory decision within approximately six months, positioning Memphasys to tap into one of the fastest-growing IVF markets globally, where demand is driven by a high prevalence of male-factor infertility and increasing use of advanced fertilisation techniques.

UK Market Entry Under CE Mark Transition Framework

While awaiting formal UK regulatory certification, Memphasys is progressing the necessary steps to commence immediate commercial sales of Felix™ under the current UK transition framework. This approach leverages the existing CE Mark certification, allowing sales without the UKCA mark for the time being, provided the company completes MHRA device registration, appoints a UK Responsible Person, and updates labelling to meet UK requirements. This strategy enables Memphasys to enter one of Europe’s largest IVF markets promptly, supported by a mix of public and private healthcare providers.

Commercial Agreements and Market Potential

Memphasys has secured a non-exclusive supply agreement with Andro Diagnostics in India, which includes a minimum commitment of 1,800 Felix™ cartridges in the first year, rising to at least 2,700 in the second year. This agreement is contingent on CDSCO approval but positions the company well to capitalise on India’s expanding network of IVF clinics. In Australia and the UK, the company is engaged in advanced commercial negotiations aimed at establishing distribution channels, console placements, and cartridge supply arrangements to support rapid market entry upon regulatory clearance.

The Felix™ System’s innovative technology offers a gentler, standardised alternative to traditional sperm preparation methods, potentially improving outcomes for patients undergoing assisted reproductive technology (ART). With approximately 103,000 ART cycles in Australia, 300,000 in India, and up to 80,000 in the UK annually, the addressable market for Felix™ is substantial and growing.

Looking Ahead

Memphasys’ coordinated regulatory and commercial strategy reflects a clear pathway to scaling its global presence. The company’s focus on direct and distribution-led sales, combined with its patented technology, could establish Felix™ as a new standard in sperm preparation. As regulatory approvals come through and commercial agreements activate, investors will be watching closely to see how quickly Memphasys can convert these milestones into revenue growth and market share gains.